Selecta Biosciences is a clinical-stage biopharmaceutical company that focuses on developing nanoparticle immunomodulatory drugs for the treatment of human diseases. The company's lead therapeutic gene therapy program, SEL-302, is aimed at improving the treatment of methylmalonic acidemia. It has several other clinical stage and preclinical product candidates to treat autoimmune diseases and IgA-mediated diseases.